Searchable abstracts of presentations at key conferences in endocrinology

ea0035p967 | Thyroid (non-cancer) | ECE2014

Usefulness of color-flow doppler ultrasonography in the differential diagnosis of thyrotoxicosis in outpatients

Merchante Agustin Angel , Fabra Amparo , Garcia Lourdes , Tolosa Mercedes , Ferrer Juan Carlos , Sanchez Carlos

Objective: To evaluate the role of thyroid blod flow assessment by color-flow Doppler ultrasonography in the differential diagnosis of thyrotoxicosis in an outpatient endocrinology clinic.Material and methods: Consecutive patients with thyrotoxicosis presenting to our center between January–December 2013 were included in the study. Clinical date were collected and measurements of TSH, serum free thyroxine and TSH receptor antibodies were performed. ...

ea0041ep69 | Adrenal cortex (to include Cushing's) | ECE2016

Hyperparathyroidism healing in patients treated for hyperaldosteronism: three cases

Blasco Lourdes Garcia , Garcia Juan Carlos Ferrer , Torrens Mercedes Tolosa , Revert Pablo Sanz , Alacid Cristian Marco , Juan Carlos Sanchez

Introduction: Hyperaldosteronism usually presents with hypertension and hypokalemia; however, there is recent evidence of a relationship with the parathyroid hormone. There are different theories to try to explain this relationship. Hyperaldosteronism treatment is medical or surgical depending upon etiology. We present three cases in which treatment solely for hyperaldosteronism also cured hyperparathyroidism.Materials and methods: We report three patien...

ea0056p606 | Obesity | ECE2018

Differences in percentage of weight loss and secondary effects after one and two months of treatment with liraglutide versus naltrexone/bupropion

Voltas Arribas Beatriz , Juan Carlos Sanchez , Garcia Juan Carlos Ferrer , Fullana Ana Artero , Revert Pablo Sanz , Alacid Cristian Marco , Merseguer Mario Lopez

Introduction: Obesity is one of the most prevalent health problems in our society. The marketing of Liraglutide and the Naltrexone/Bupropion combination has been given the green light.Objectives: To analyze the differences in a series of 19 patients assigned to treatment with Liraglutide or Naltrexone/Bupropion.Material and methods: A descriptive analysis was carried out using Stata. 19 patients were included, 9 were treated with L...

ea0090ep437 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Real-world effectiveness analysis of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus

Ferrer Garcia Juan Carlos , Albalat-Galera Raquel , Moya Victor Atienza , Hernandez Jessica Sanchez , Palomar Luis Arribas , Casamayor Ignacio Ramos , Fullana Ana Artero , Blanco Cintia Gonzalez , Portilla Ana Jimenez , Juan Carlos Sanchez

Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.Methods: Retrospective real-world efficacy analysis including aGLP1-...